Anbio Biotechnology
NNNN
$7.09
-$0.085-1.19%
| Weiss Ratings | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.09% | |||
| 30-Day Total Return | 15.66% | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | 22.88% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -8.25% | |||
| 52-Week Low % Change | 38.51% | |||
| Price | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.82 | |||
| 52-Week Low Price | $5.18 | |||
| 52-Week Low Price (Date) | Feb 19, 2025 | |||
| 52-Week High Price (Date) | Apr 03, 2025 | |||
| Valuation | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 314.92M | |||
| Enterprise Value | 304.61M | |||
| Price/Earnings (TTM) | 79.55 | |||
| Earnings Per Share (TTM) | 0.09 | |||
| Earnings Per Share Growth | 750.94% | |||
| Price/Earnings To Growth | 0.11 | |||
| Price/Sales (TTM) | 31.95 | |||
| Price/Book (Q) | 16.48 | |||
| Enterprise Value/Revenue (TTM) | 32.06 | |||
| Price | $7.09 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | 73.61 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 42.29M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 49 16 0962 47281 | |||
| Address | -- | |||
| Website | www.anbio.com | |||
| Country | Germany | |||
| Year Founded | 2021 | |||
| Profitability | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 43.54% | |||
| Profit Margin | 45.56% | |||
| Management Effectiveness | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 15.05% | |||
| Return on Equity | 26.64% | |||
| Income Statement | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.50M | |||
| Total Revenue (TTM) | 9.50M | |||
| Revenue Per Share | $0.23 | |||
| Gross Profit (TTM) | 5.47M | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | 4.14M | |||
| Net Income (TTM) | 4.33M | |||
| Net Income Avl. to Common (TTM) | 4.33M | |||
| Total Revenue Growth (Q YOY) | 91.19% | |||
| Earnings Growth (Q YOY) | 136.53% | |||
| EPS Diluted (TTM) | 0.09 | |||
| EPS Diluted Growth (Q YOY) | 701.89% | |||
| Balance Sheet | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 10.31M | |||
| Cash Per Share (Q) | $0.24 | |||
| Total Current Assets (Q) | 18.77M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 18.42M | |||
| Current Ratio (Q) | 35.555 | |||
| Book Value Per Share (Q) | $0.44 | |||
| Total Assets (Q) | 18.94M | |||
| Total Current Liabilities (Q) | 527.80K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 527.80K | |||
| Total Common Equity (Q) | 18.42M | |||
| Cash Flow | NNNN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 285.20K | |||
| Cash from Financing (TTM) | 98.20K | |||
| Net Change in Cash (TTM) | -250.80K | |||
| Levered Free Cash Flow (TTM) | -359.10K | |||
| Cash from Operations (TTM) | -634.20K | |||
